L3VLUP
ProSign in

SANA · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SANAAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SANA
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterSANAAMGN
Q3 2020none listed holders, n.a.16 holders, $16.3bn
Q4 2020none listed holders, n.a.19 holders, $14.0bn
Q1 20214 holders, $398m16 holders, $14.5bn
Q2 20213 holders, $259m23 holders, $13.8bn
Q3 20214 holders, $297m24 holders, $11.6bn
Q4 20214 holders, $206m21 holders, $10.4bn
Q1 20223 holders, $106m23 holders, $9.9bn
Q2 20223 holders, $80m28 holders, $9.7bn
Q3 20223 holders, $74m21 holders, $7.9bn
Q4 20223 holders, $46m24 holders, $9.3bn
Q1 20233 holders, $38m22 holders, $8.4bn
Q2 20233 holders, $76m26 holders, $7.4bn
Q3 20233 holders, $47m26 holders, $8.7bn
Q4 20233 holders, $50m24 holders, $8.4bn
Q1 20244 holders, $171m25 holders, $6.7bn
Q2 20243 holders, $91m20 holders, $8.0bn
Q3 20243 holders, $68m21 holders, $8.8bn
Q4 20242 holders, $26m20 holders, $8.2bn
Q1 20252 holders, $26m25 holders, $12.0bn
Q2 20251 holders, $27m20 holders, $10.2bn
Q3 20251 holders, $41m17 holders, $10.4bn
Q4 20251 holders, $27m19 holders, $18.0bn
Q1 20261 holders, $19m15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
SANA

Sana Biotechnology Inc

Holders
3
Reported value
$91m
Buyers
0
Sellers
2

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
20
Reported value
$8.0bn
Buyers
11
Sellers
9

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2024

Among the 22 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SANA (2)

Baillie Gifford & Co, Capital World Investors

Only AMGN (19)

AllianceBernstein LP, ARK Investment Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →